Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 200

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 200
---
arrants, which were originally issued concurrently with the IPO in a private placement to Cantor at a price of $1.50 per Warrant, with each warrant exercisable for one share of Common Stock at $11.50 per share; |

| ● | up to 700,000 shares of Common Stock issued to Cantor in settlement of $7.0 million in deferred underwriting fees; and |

| ● | up to 350,000 shares of Common Stock issued to Alta pursuant to a settlement and release agreement. |

In addition, this prospectus relates to the issuance of up to 6,900,000 shares of Common Stock that are issuable upon the exercise of the Public Warrants, at an exercise price per share of $11.50, contained in the units sold at a price of $10.00 per unit in the IPO. The Common Stock being registered for resale in connection with this offering will constitute a considerable percentage of our outstanding shares of Common Stock. We are registering for resale on behalf of the Selling Securityholders an aggregate of 19,619,406 shares of Common Stock, not including the shares underlying the Warrants. The shares of Common Stock being registered for resale in this prospectus (excluding the shares underlying the Warrants) constitutes approximately 72.5% of our total outstanding shares. The Selling Securityholders, including Chris Kim, Liminatus’ Founder and our Chief Executive Officer, the beneficial owner of approximately 23.1% of our outstanding shares of Common Stock, will be able to sell all of their shares for so long as the registration statement of which this prospectus forms a part is available for use. Given the substantial amount of redemptions in connection with the Business Combination and the relative lack of liquidity in our stock, sales of our Common Stock under the registration statement of which this prospectus is a part could result in a significant decline in the market price of our securities. In addition, a portion of the Common Stock being registered for resale hereunder were purchased by the Selling Securityholders at prices below the current market price of our Common Stock and, accordingly, may be or are incentivized to sell them under the registration statement of which this prospectus is a part (for example, the Sponsor purchased the founder shares at a price per share of $0.004). The Selling Securityholders may be incentivized to sell their securities even if the prevailing trading price of such securities is at or significantly below the IPO price, because the prices at which they acquired their shares may be lower